Skip to main content
SpringerLink
Log in

Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Acromegaly is associated with increased morbidity and mortality from cardiovascular disease. Inflammatory markers, such as C-reactive protein and leucocyte count, haemostatic markers, such as fibrinogen and factor VIII and cardiac hypertrophy marker, B-type natriuretic peptide, have emerged as important cardiovascular risk markers in the general population. The objective of this study was to assess the serum levels of conventional, inflammatory, haemostatic markers and NT-pro BNP in mostly non-diabetic normotensive patients with acromegaly, as well as the effect of 6 months of octreotide LAR therapy on these markers. We studied 12 patients with active acromegaly, 12 patients in whom remission of acromegaly had been achieved by surgery and 12 healthy control subjects matched for age, gender and body mass index. At baseline fasting blood was obtained for measurements of GH, IGF-1, glucose, insulin, lipids, lipoprotein (a), C-reactive protein, leucocyte count, fibrinogen, factor VIII and NT-pro BNP. After baseline evaluation, patients with active acromegaly were treated with octreotide LAR for 24 weeks. At 24 weeks, measurements were repeated as on baseline. Insulin resistance index and fibrinogen levels were higher in patients with active acromegaly than patients and subjects in control groups. CRP, leucocyte count, factor VIII and NT-pro BNP were similar in the three groups. Octreotide LAR reduced GH, IGF-1 and insulin resistance index but did not alter levels of CRP and NT-pro BNP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12(1):71–79

    CAS  Google Scholar 

  2. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446

    Article  PubMed  CAS  Google Scholar 

  3. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendocrinology 83(3–4):211–217

    Article  PubMed  CAS  Google Scholar 

  4. Colao A, Pivonello R, Marzullo P, Auriemma RS, De Martino MC, Ferone D, Lombardi G (2005) Severe systemic complications of acromegaly. J Endocrinol Invest 28(5 Suppl):65–77

    PubMed  CAS  Google Scholar 

  5. Vitale G, Pivonello R, Lombardi G, Colao A (2004) Cardiovascular complications in acromegaly. Minerva Endocrinol 29(3):77–88

    PubMed  CAS  Google Scholar 

  6. Vitale G, Pivonello R, Lombardi G, Colao A (2004) Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol 3(5):309–318

    Article  PubMed  Google Scholar 

  7. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152

    Article  PubMed  CAS  Google Scholar 

  8. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G (2004) The heart: an end-organ of GH action. Eur J Endocrinol 151(Suppl 1):S93–S101

    Article  PubMed  CAS  Google Scholar 

  9. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G (2003) High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88(7):3196–3201

    Article  PubMed  CAS  Google Scholar 

  10. Colao A (2001) Are patients with acromegaly at high risk for dysrhythmias? Clin Endocrinol (Oxf) 55(3):305–306

    Article  CAS  Google Scholar 

  11. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A (2005) Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 63(4):470–476

    Article  Google Scholar 

  12. Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397

    Article  PubMed  CAS  Google Scholar 

  13. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663

    Article  PubMed  CAS  Google Scholar 

  14. Danesh J, Lewington S, Thompson SG et al (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799–1809 [Erratum, JAMA 2005;294: 2848.]

    Article  PubMed  CAS  Google Scholar 

  15. Cushman M, Lemaitre RN, Kuller LH et al (1999) Fibrinolytic activation markers predict myocardial infarction in the elderly: the cardiovascular health study. Arterioscler Thromb Vasc Biol 19:493–498

    PubMed  CAS  Google Scholar 

  16. Mangoni AA, Jackson SH (2002) Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 112:556–565

    Article  PubMed  CAS  Google Scholar 

  17. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 47(3):287–296

    Article  CAS  Google Scholar 

  18. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692–1699

    Article  PubMed  CAS  Google Scholar 

  19. Andreassen M, Faber J, Vestergaard H, Kristorp C, Kristensen LO (2007) N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol 66:619–625 E-print

    Article  CAS  Google Scholar 

  20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419

    Article  PubMed  CAS  Google Scholar 

  21. Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 46(1):69–74

    Article  CAS  Google Scholar 

  22. Colao A, Marzullo P, Lombardi G (2002) Effect of six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303–309

    Article  PubMed  CAS  Google Scholar 

  23. Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Somma C, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87(7):3097–3104

    Article  PubMed  CAS  Google Scholar 

  24. Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P (2000) Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 53(4):445–451

    Article  CAS  Google Scholar 

  25. Ronchi CL, Corbetta S, Cappiello V, Morpurgo PS, Giavoli C, Beck-Peccoz P, Arosio M, Spada A (2004) Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. Eur J Endocrinol 150(5):663–669

    Article  PubMed  CAS  Google Scholar 

  26. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jaques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agonistino RB, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. New Engl J Med 355(25):2631–2639

    Article  PubMed  CAS  Google Scholar 

  27. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G (2001) Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54(4):515–524

    Article  CAS  Google Scholar 

  28. Mattace-Raso F, van Popele NM, Schalekamp MA, van der Cammen TJ (2002) Intima-media thickness of the common carotid arteries is related to coronary atherosclerosis and left ventricular hypertrophy in older adults. Angiology 53(5):569–574

    Article  PubMed  Google Scholar 

  29. Lacroix P, Aboyans V, Espaliat E, Cornu E, Virot P, Laskar M (2003) Carotid intima-media thickness as predictor of secondary events after coronary angioplasty. Int Angiol 22(3):279–283

    PubMed  CAS  Google Scholar 

  30. Takiuchi S, Rakugi H, Fujii H, Kamide K, Horio T, Nakatani S, Kawano Y, Higaki J, Ogihara T (2003) Carotid intima-media thickness is correlated with impairment of coronary flow reserve in hypertensive patients without coronary artery disease. Hypertens Res 26(12):945–951

    Article  PubMed  Google Scholar 

  31. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85(1):193–199

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by an unrestricted research grant from Novartis Canada. We would like to thank Mr. R. Boileau, statistician at the CHUM, for performing the statistical analyses.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, Centre Universitaire de l’Université de Montréal (CHUM) Research Center, Notre-Dame Hospital, 1560, rue Sherbrooke E, Montreal, Quebec, Canada, H2L 4M1

    Brian J. Potter, Catherine Beauregard & Omar Serri

Authors
  1. Brian J. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Beauregard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar Serri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Omar Serri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Potter, B.J., Beauregard, C. & Serri, O. Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR. Pituitary 11, 49–53 (2008). https://doi.org/10.1007/s11102-007-0067-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-007-0067-1

Keywords

Search

Navigation